Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

So much has been written about the significant levels of insider selling taking place at the moment. With that in mind, we wanted to focus on the companies that are bucking the trend.

To create this list, we started with a selection of cash-rich companies. All of these companies have cash holdings that exceed more than 4 quarters of average operating expenses.

To refine the list, we collected data on insider buying, and identified the names that have seen bullishness from company executives, with net insider purchases representing at least 2% of share float.

(click to enlarge)

Inside management thinks these cash-rich companies are due for a rally--do you agree? Use this list as a starting point for your own analysis.

List sorted by cash to operating expense ratio.

1. Pharmacyclics Inc. (NASDAQ:PCYC): Operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Market cap at $2.02B, most recent closing price at $29.47. Average quarterly operating expense over the last five quarters at $14.85M, vs. most recent cash and short term investments at $214.96M, implies a Cash / Avg. Operating Expense ratio at 14.48. Over the last six months, insiders were net buyers of 1,340,060 shares, which represents about 2.47% of the company's 54.35M share float.

2. Endocyte, Inc. (NASDAQ:ECYT): Engages in developing targeted therapies for the treatment of cancer and inflammatory diseases. Market cap at $234.75M, most recent closing price at $6.36. Average quarterly operating expense over the last five quarters at $9.67M, vs. most recent cash and short term investments at $117.89M, implies a Cash / Avg. Operating Expense ratio at 12.19. Over the last six months, insiders were net buyers of 666,000 shares, which represents about 2.51% of the company's 26.54M share float.

3. Myrexis, Inc. (OTCPK:MYRX): Engages in discovering, developing, and commercializing small molecule drugs for the treatment of cancer. Market cap at $72.97M, most recent closing price at $2.71. Average quarterly operating expense over the last five quarters at $9.11M, vs. most recent cash and short term investments at $80.7M, implies a Cash / Avg. Operating Expense ratio at 8.86. Over the last six months, insiders were net buyers of 441,170 shares, which represents about 2.03% of the company's 21.76M share float.

4. Evolution Petroleum Corp. (NYSEMKT:EPM): Engages in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas in Louisiana. Market cap at $233.69M, most recent closing price at $8.39. Average quarterly operating expense over the last five quarters at $2.09M, vs. most recent cash and short term investments at $15.47M, implies a Cash / Avg. Operating Expense ratio at 7.4. Over the last six months, insiders were net buyers of 782,038 shares, which represents about 4.95% of the company's 15.79M share float.

5. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Market cap at $361.82M, most recent closing price at $4.50. Average quarterly operating expense over the last five quarters at $18.18M, vs. most recent cash and short term investments at $128.01M, implies a Cash / Avg. Operating Expense ratio at 7.04. Over the last six months, insiders were net buyers of 1,351,460 shares, which represents about 2.4% of the company's 56.37M share float.

6. VMware, Inc. (NYSE:VMW): Provides virtualization and virtualization-based cloud infrastructure solutions primarily in the United States. Market cap at $42.55B, most recent closing price at $99.91. Average quarterly operating expense over the last five quarters at $773.99M, vs. most recent cash and short term investments at $5222.26M, implies a Cash / Avg. Operating Expense ratio at 6.75. Over the last six months, insiders were net buyers of 3,295,564 shares, which represents about 4.16% of the company's 79.14M share float.

7. Halozyme Therapeutics, Inc. (NASDAQ:HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. Market cap at $771.97M, most recent closing price at $7.53. Average quarterly operating expense over the last five quarters at $19.7M, vs. most recent cash and short term investments at $116.61M, implies a Cash / Avg. Operating Expense ratio at 5.92. Over the last six months, insiders were net buyers of 1,934,950 shares, which represents about 2.93% of the company's 66.14M share float.

8. ViroPharma Inc. (VPHM): Engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Market cap at $1.4B, most recent closing price at $19.83. Average quarterly operating expense over the last five quarters at $83.55M, vs. most recent cash and short term investments at $473.36M, implies a Cash / Avg. Operating Expense ratio at 5.67. Over the last six months, insiders were net buyers of 2,020,227 shares, which represents about 3.22% of the company's 62.83M share float.

*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally?